RxDoctor Payments Data

Scott Lundgren, DO

Advanced Heart Failure and Transplant Cardiology · Omaha, NENPI 1487092086

Payments from drug & device makers

$230,053in general payments, 2019–2025

Across 549 payments — averaging $419.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$160K
  • Bayer$53K
  • Medtronic$11K
  • Cvrx, Inc.$2K
  • Abiomed$1K
  • One Lambda, Inc.$1K
  • plus $1K from 11 others

What the payments were for

  • Consulting fees$112,02162%
  • Speaking & faculty fees$3,5192%
  • Grants$8,7505%
  • Travel & lodging$39,12022%
  • Food & beverage$15,8189%
  • Education$1830%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in Nebraskato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$117,971
Medicare patients
568
Services billed
1,616

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol180$156,843
EntrestoSacubitril/Valsartan131$141,780
JardianceEmpagliflozin103$107,694
EliquisApixaban64$73,236
XareltoRivaroxaban14$12,117
MounjaroTirzepatide11$11,569
Sildenafil Citrate33$11,440
Mycophenolic AcidMycophenolate Sodium12$9,879
CorlanorIvabradine Hcl13$9,779
Tacrolimus27$4,446
Torsemide108$4,235
Metoprolol Succinate186$2,968
Potassium Chloride33$2,002
Eplerenone24$1,977
Spironolactone244$1,608

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$18$156,843180 claims
NovartisEntresto$397$141,780131 claims
PfizerEliquis$42$73,23664 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Nebraskaon file to place this against a meaningful peer group, so we don't.

Other advanced heart failure and transplant cardiology in Omaha

Where these figures come from

Is this you, or does something look wrong? →